BRISTOL-MYERS SQUIBB COMPANY Income (Loss) from Continuing Operations, Per Diluted Share
BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Income (Loss) from Continuing Operations, Per Diluted Share of $2.16 per share for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-17.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2012-02-17
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, per diluted share for the quarter ending 2010-12-31 was $0.28, a 31.71% decline year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, per diluted share for the quarter ending 2010-09-30 was $0.55, a 22.22% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, per diluted share for the quarter ending 2010-06-30 was $0.53, a 20.45% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, per diluted share for the quarter ending 2010-03-31 was $0.43, a 30.30% increase year-over-year.
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, per diluted share for fiscal 2011 was $2.16, a 20.67% increase from fiscal 2010.
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, per diluted share for fiscal 2010 was $1.79, a 9.82% increase from fiscal 2009.
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, per diluted share for fiscal 2009 was $1.63, a 20.74% increase from fiscal 2008.
- BRISTOL-MYERS SQUIBB COMPANY income (loss) from continuing operations, per diluted share for fiscal 2008 was $1.35, a 107.69% increase from fiscal 2007.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month | Income (Loss) from Continuing Operations, Per Diluted Share 3 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 6 month | Income (Loss) from Continuing Operations, Per Diluted Share 6 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 9 month | Income (Loss) from Continuing Operations, Per Diluted Share 9 month as first filed | Income (Loss) from Continuing Operations, Per Diluted Share 12 month |
|---|---|---|---|---|---|---|---|
| 2011-12-31 | $2.16 10-K · filed 2012-02-17 | ||||||
| 2010-12-31 | $0.28 10-K · filed 2011-02-18 | $1.79 10-K · filed 2012-02-17 | |||||
| 2010-09-30 | $0.55 10-K · filed 2011-02-18 | $1.51 10-Q · filed 2010-10-26 | |||||
| 2010-06-30 | $0.53 10-K · filed 2011-02-18 | $0.96 10-Q · filed 2010-07-22 | |||||
| 2010-03-31 | $0.43 10-K · filed 2011-02-18 | ||||||
| 2009-12-31 | $0.41 10-K · filed 2011-02-18 | $1.63 10-K · filed 2012-02-17 | |||||
| 2009-09-30 | $0.45 10-K · filed 2011-02-18 | $0.48 10-Q · filed 2009-10-22 | $1.21 10-Q · filed 2010-10-26 | $1.30 10-Q · filed 2009-10-22 | |||
| 2009-06-30 | $0.44 10-K · filed 2011-02-18 | $0.49 10-Q · filed 2009-07-23 | $0.77 10-Q · filed 2010-07-22 | $0.81 10-Q · filed 2009-07-23 | |||
| 2009-03-31 | $0.33 10-K · filed 2011-02-18 | ||||||
| 2008-12-31 | $1.35 10-K · filed 2011-02-18 | ||||||
| 2008-09-30 | $0.29 10-Q · filed 2009-10-22 | $0.98 10-Q · filed 2009-10-22 | |||||
| 2008-06-30 | $0.36 10-Q · filed 2009-07-23 | $0.68 10-Q · filed 2009-07-23 | |||||
| 2007-12-31 | $0.65 10-K · filed 2010-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |